Boothwyn, PA, United States of America

Sanath K Meegalla

USPTO Granted Patents = 42 


 

Average Co-Inventor Count = 6.4

ph-index = 8

Forward Citations = 200(Granted Patents)


Location History:

  • Devon, PA (US) (2002 - 2003)
  • Boothwyn, PA (US) (2006 - 2014)
  • Garnet, NJ (US) (2015 - 2016)
  • Garnet Valley, PA (US) (2014 - 2021)

Company Filing History:


Years Active: 2002-2021

Loading Chart...
Loading Chart...
Loading Chart...
42 patents (USPTO):Explore Patents

Title: Sanath K Meegalla: Innovator in Diabetes Treatment Technologies

Introduction: Sanath K Meegalla is an accomplished inventor based in Boothwyn, Pennsylvania, with a remarkable portfolio of 42 patents. His work focuses on innovative compounds and methods aimed at treating type II diabetes, particularly through the modulation of the GPR40 receptor.

Latest Patents: Among his latest innovations, Meegalla has developed cyclohexyl GPR40 agonists designed for the treatment of type II diabetes. These compounds and compositions offer a new approach to managing disorders influenced by GPR40 receptor modulation. Additionally, he has introduced substituted benzothiophenyl derivatives as GPR40 agonists for similar therapeutic applications, further expanding the possibilities for diabetes treatment. Each of these compounds is characterized by specific structural formulas that showcase their potential efficacy.

Career Highlights: Over the years, Sanath K Meegalla has made significant contributions while working with reputable organizations such as Janssen Pharmaceutica and 3-Dimensional Pharmaceuticals, Inc. His experience in these companies has equipped him with the expertise needed to innovate in the pharmaceutical field.

Collaborations: Throughout his career, Meegalla has collaborated with talented individuals like Jinsheng Chen and Carl R. Illig. These partnerships underline the importance of teamwork in driving advancements in biomedical research and patentable inventions.

Conclusion: Sanath K Meegalla’s innovative work in the development of compounds for the treatment of type II diabetes exemplifies his dedication to advancing medical science. His extensive patent portfolio not only highlights his achievements but also signifies his ongoing commitment to finding effective treatments for chronic health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…